Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
IBRX US​

ImmunityBio, Inc.(IBRX US)

$8.22-0.091.08%Ext:$8.24+0.020.25%(Market Closed · 23:56:40 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees

SEC Filings

Financials(45)

Expand
  • 10-QQ2ended 30 Jun 20264 Aug
  • 10-QQ1ended 31 Mar 20267 May
  • 10-KFY 2025ended 31 Dec 202523 Feb
  • 10-QQ3ended 30 Sept 20254 Nov 2025
  • 10-QQ2ended 30 Jun 20255 Aug 2025
  • 10-QQ1ended 31 Mar 202512 May 2025
  • 10-KFY 2024ended 31 Dec 20243 Mar 2025
  • 10-QQ3ended 30 Sept 202412 Nov 2024
  • 10-QQ2ended 30 Jun 202412 Aug 2024
  • 10-QQ1ended 31 Mar 20249 May 2024
  • 10-KFY 2023ended 31 Dec 202319 Mar 2024
  • 10-QQ3ended 30 Sept 20239 Nov 2023
  • 10-QQ2ended 30 Jun 20238 Aug 2023
  • 10-QQ1ended 31 Mar 202311 May 2023
  • 10-KFY 2022ended 31 Dec 20221 Mar 2023

Events(100)

Expand
  • 8-KFDA Expands ANKTIVA®Approval forBCG-UnresponsiveNon-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease14 Oct
  • 8-KResults of Operations and Financial Condition4 Aug
  • 8-KRegulation FD Disclosure30 Jul
  • 8-KSubmission of Matters to a Vote of Security Holders10 Jun
  • 8-KImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States18 May
  • 8-KResults of Operations and Financial Condition7 May
  • 8-KResults of Operations and Financial Condition9 Apr
  • 8-KImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance6 Apr
  • 8-KImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million ofNon-DilutiveFinancing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline31 Mar
  • 8-KResults of Operations and Financial Condition23 Feb
  • 8-KOther Events18 Feb
  • 8-KEntry into a Material Definitive Agreement26 Jan
  • 8-KResults of Operations and Financial Condition15 Jan
  • 8-KOther Events14 Jan
  • 8-KEntry into a Material Definitive Agreement23 Dec 2025

Insider Ownership(251)

Expand
  • 4Statement of changes in beneficial ownership6 Oct
  • 4Statement of changes in beneficial ownership6 Oct
  • 4Statement of changes in beneficial ownership6 Jul
  • 4Statement of changes in beneficial ownership6 Jul
  • 4Statement of changes in beneficial ownership1 Jul
  • 4Statement of changes in beneficial ownership26 Jun
  • 4Statement of changes in beneficial ownership10 Jun
  • 4Statement of changes in beneficial ownership10 Jun
  • 4Statement of changes in beneficial ownership10 Jun
  • 4Statement of changes in beneficial ownership10 Jun
  • 4Statement of changes in beneficial ownership10 Jun
  • 4Statement of changes in beneficial ownership10 Jun
  • 4Statement of changes in beneficial ownership5 Jun
  • 4Statement of changes in beneficial ownership2 Apr
  • 4Statement of changes in beneficial ownership26 Feb

Beneficial Ownership(19)

Expand
  • SC 13D/AImmunityBio, Inc.6 Aug
  • SC 13D/AImmunityBio, Inc.25 Feb
  • SC 13D/AImmunityBio, Inc.10 Nov 2025
  • SC 13D/AImmunityBio, Inc.4 Jan 2024
  • SC 13D/AImmunityBio, Inc.21 Sep 2023
  • SC 13D/AImmunityBio, Inc.23 May 2023
  • SC 13D/AImmunityBio, Inc.7 Dec 2022
  • SC 13D/AImmunityBio, Inc.12 Mar 2021
  • SC 13D/ANantKwest, Inc.21 Dec 2020
  • SC 13D/ANantKwest, Inc.29 Jun 2020
  • SC 13D/ANantKwest, Inc.1 Apr 2019
  • SC 13GNantKwest, Inc.13 Feb 2018
  • SC 13G/ANantKwest, Inc.13 Feb 2018
  • SC 13G/ANantKwest, Inc.13 Feb 2017
  • SC 13D/ANantKwest, Inc.11 Jul 2016

Other Ownership(11)

Expand
  • 144Simon Barry J.5 Oct
  • 144Cohen Cheryl2 Oct
  • 144Cohen Cheryl2 Jul
  • 144Selecky Christobel1 Jul
  • 144Selecky Christobel30 Jun
  • 144Selecky Christobel29 Jun
  • 144Simon Barry J.4 Jun
  • 144Selecky Christobel23 Feb
  • 144Selecky Christobel20 Jan
  • 144Simon Barry J.20 Jan
  • 144Selecky Christobel16 Jan

Proxies(27)

Expand
  • DEFA14ADefinitive additional materials29 Apr
  • DEF 14ADefinitive proxy statement29 Apr
  • ARSAnnual report to security holders29 Apr
  • DEF 14CDefinitive information statement20 Oct 2025
  • PRE 14CPreliminary information statement8 Oct 2025
  • DEFA14ADefinitive additional materials30 Apr 2025
  • ARSAnnual report to security holders30 Apr 2025
  • DEF 14ADefinitive proxy statement30 Apr 2025
  • DEFA14ADefinitive additional materials29 Apr 2024
  • DEF 14ADefinitive proxy statement29 Apr 2024
  • ARSAnnual report to security holders29 Apr 2024
  • DEF 14CDefinitive information statement28 Sep 2023
  • PRE 14CPreliminary information statement18 Sep 2023
  • DEF 14ADefinitive proxy statement28 Apr 2023
  • ARSAnnual report to security holders28 Apr 2023

Registrations(60)

Expand
  • 424B5Prospectus filing (Rule 424(b)(5))23 Dec 2025
  • 424B5Prospectus filing (Rule 424(b)(5))28 Jul 2025
  • S-8Registration statement (employee benefit plan)23 Jun 2025
  • 424B5Prospectus filing (Rule 424(b)(5))8 Apr 2025
  • 424B5Prospectus filing (Rule 424(b)(5))12 Dec 2024
  • 424B5Prospectus filing (Rule 424(b)(5))10 Dec 2024
  • S-8Registration statement (employee benefit plan)20 Jun 2024
  • S-3ASRAutomatic shelf registration statement (S-3)17 Apr 2024
  • 424B5Prospectus filing (Rule 424(b)(5))25 Jul 2023
  • 424B5Prospectus filing (Rule 424(b)(5))24 Jul 2023
  • 424B5Prospectus filing (Rule 424(b)(5))16 Feb 2023
  • S-3Registration statement (primary offering)7 Feb 2023
  • 424B5Prospectus filing (Rule 424(b)(5))12 Dec 2022
  • S-3MEFRegistration statement (additional securities, S-3)12 Dec 2022
  • 424B5Prospectus filing (Rule 424(b)(5))12 Dec 2022

Filing Review Correspondence(13)

Expand
  • CORRESPFiling review correspondence30 Apr 2024
  • CORRESPFiling review correspondence28 Mar 2024
  • CORRESPFiling review correspondence8 Feb 2023
  • CORRESPFiling review correspondence5 Jan 2023
  • CORRESPFiling review correspondence29 Aug 2019
  • CORRESPFiling review correspondence23 Aug 2016
  • CORRESPFiling review correspondence24 Jul 2015
  • CORRESPFiling review correspondence24 Jul 2015
  • CORRESPFiling review correspondence15 Jul 2015
  • CORRESPFiling review correspondence13 Jul 2015
  • CORRESPFiling review correspondence6 Jul 2015
  • CORRESPFiling review correspondence2 Jul 2015
  • CORRESPFiling review correspondence19 Jun 2015

SEC Orders And Notices(9)

Expand
  • EFFECTNotice of effectiveness2 May 2024
  • EFFECTNotice of effectiveness9 Feb 2023
  • EFFECTNotice of effectiveness18 May 2022
  • EFFECTNotice of effectiveness26 May 2021
  • EFFECTNotice of effectiveness1 Feb 2021
  • EFFECTNotice of effectiveness3 Sep 2019
  • EFFECTNotice of effectiveness26 Aug 2016
  • CT ORDERConfidential treatment order28 Jul 2015
  • EFFECTNotice of effectiveness27 Jul 2015

Exempt Offerings(9)

Expand
  • D06b22 Sep 2023
  • D06b22 Jul 2022
  • D06b5 Aug 2015
  • D/A06b17 Jul 2015
  • D06b24 Jun 2015
  • D06b5 Jan 2015
  • D06b29 Dec 2014
  • D06b17 Apr 2014
  • DNotice of exempt offering of securities (Reg D)9 Oct 2009

Other(1)

Expand
  • CERTNASAUTO-GENERATED PAPER DOCUMENT24 Jul 2015